PMID- 35783675
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220928
IS  - 1319-0164 (Print)
IS  - 2213-7475 (Electronic)
IS  - 1319-0164 (Linking)
VI  - 30
IP  - 8
DP  - 2022 Aug
TI  - Comparison of the post-marketing safety profile between influenza and COVID-19 
      vaccines: An analysis of the vaccine adverse event reporting system.
PG  - 1137-1142
LID - 10.1016/j.jsps.2022.06.009 [doi]
AB  - The global coronavirus disease (COVID-19) epidemic can be partially managed by 
      vaccines; however, the public must be informed about the safety of COVID-19 
      vaccines to avoid hesitancy. Therefore, it is important to know the safety 
      profile of the COVID-19 vaccine by comparison to that of a well-known vaccine, 
      such as the influenza vaccine. Hence, this retrospective descriptive study was 
      conducted to evaluate and compare the number of adverse effects (AEs) reported to 
      the Vaccine Adverse Event Reporting System (VAERS) for both COVID-19 and 
      influenza vaccines, identify the most common AEs of each vaccine, and compare the 
      frequency and outcomes of using COVID-19 and influenza vaccines in the U.S. 
      population. Surveillance reports from 1st December 2020 to 8th October 2021 of 
      both vaccines were retrieved from the U.S. VAERS. A total of 544,025 and 15,871 
      reports of post-COVID-19 and - influenza vaccine AEs were reported to the VAERS, 
      respectively. Females reported > 58% and nearly 70% of influenza - and COVID-19 
      vaccine-associated AEs, respectively. The estimated incidence rates of AEs 
      associated with COVID-19 and influenza vaccines in the U.S. were 1.36 and 0.12 
      per 1,000 persons, respectively. The incidence of AEs was higher among COVID-19 
      vaccine recipients than that among influenza vaccine recipients. COVID-19 vaccine 
      recipients have a two-fold higher risk of mortality and life-threatening events 
      than influenza vaccine recipients. However, most of the reported AEs were similar 
      between the two vaccines in terms of symptoms.
CI  - (c) 2022 The Author(s).
FAU - Al-Ahmari, Abdullah K
AU  - Al-Ahmari AK
AD  - College of Pharmacy, Department of Clinical Pharmacy, Prince Sattam Bin Abdulaziz 
      University, Al-Kharj, Saudi Arabia.
FAU - AlAsmari, Amnah
AU  - AlAsmari A
AD  - College of Pharmacy, Department of Clinical Pharmacy, Prince Sattam Bin Abdulaziz 
      University, Al-Kharj, Saudi Arabia.
FAU - AlKorbi, Anoud
AU  - AlKorbi A
AD  - College of Pharmacy, Department of Clinical Pharmacy, Prince Sattam Bin Abdulaziz 
      University, Al-Kharj, Saudi Arabia.
FAU - Ahmed, Nehad J
AU  - Ahmed NJ
AD  - College of Pharmacy, Department of Clinical Pharmacy, Prince Sattam Bin Abdulaziz 
      University, Al-Kharj, Saudi Arabia.
FAU - Almalki, Ziyad S
AU  - Almalki ZS
AD  - College of Pharmacy, Department of Clinical Pharmacy, Prince Sattam Bin Abdulaziz 
      University, Al-Kharj, Saudi Arabia.
FAU - Alshehri, Ahmed M
AU  - Alshehri AM
AD  - College of Pharmacy, Department of Clinical Pharmacy, Prince Sattam Bin Abdulaziz 
      University, Al-Kharj, Saudi Arabia.
FAU - Albassam, Ahmed A
AU  - Albassam AA
AD  - College of Pharmacy, Department of Clinical Pharmacy, Prince Sattam Bin Abdulaziz 
      University, Al-Kharj, Saudi Arabia.
FAU - Alem, Ghada M
AU  - Alem GM
AD  - College of Pharmacy, Department of Clinical Pharmacy, Prince Sattam Bin Abdulaziz 
      University, Al-Kharj, Saudi Arabia.
LA  - eng
PT  - Journal Article
DEP - 20220621
PL  - Saudi Arabia
TA  - Saudi Pharm J
JT  - Saudi pharmaceutical journal : SPJ : the official publication of the Saudi 
      Pharmaceutical Society
JID - 9705695
PMC - PMC9232269
OTO - NOTNLM
OT  - Adverse effects
OT  - COVID-19 vaccine
OT  - Influenza vaccine
OT  - Safety
OT  - Symptoms
COIS- The authors declare that they have no known competing financial interests or 
      personal relationships that could have appeared to influence the work reported in 
      this paper.
EDAT- 2022/07/06 06:00
MHDA- 2022/07/06 06:01
PMCR- 2022/06/21
CRDT- 2022/07/05 10:14
PHST- 2022/03/31 00:00 [received]
PHST- 2022/06/17 00:00 [accepted]
PHST- 2022/07/06 06:00 [pubmed]
PHST- 2022/07/06 06:01 [medline]
PHST- 2022/07/05 10:14 [entrez]
PHST- 2022/06/21 00:00 [pmc-release]
AID - S1319-0164(22)00157-8 [pii]
AID - 10.1016/j.jsps.2022.06.009 [doi]
PST - ppublish
SO  - Saudi Pharm J. 2022 Aug;30(8):1137-1142. doi: 10.1016/j.jsps.2022.06.009. Epub 
      2022 Jun 21.